The Potential Prognostic Value of Dual-Imaging PET Parameters Based on 18F-FDG and 18F-OC for Neuroendocrine Neoplasms
Table 1
Patient characteristics.
Characteristic
Value
Total number of patients
66
Age (year)
Gender
Male:46, female: 20
Primary tumor site ( %)
Pancreas
23 (34.8%)
Gastrointestinal
25 (37.9%)
Bronchopulmonary
3 (4.6%)
Othersa
15 (22.7%)
WHO 2010 Grade (n %)
G1
14 (21.2%)
G2
30 (45.5%)
G3
22 (33.3%)
Time since diagnosis (weeks)
0-346
Treatment
Before PET/CT
Surgical
22 (33.3%)
33Medicalb
18 (27.3%)
Liver-directed treatmentc
2 (3.0%)
Radiation
2 (3.0%)
No treatment
30 (45.5%)
After PET/CT
Surgical
11 (16.7%)
Medicalb
48 (72.7%)
Liver-directed treatmentc
11 (16.7%)
Radiation
5 (7.6%)
No treatment
7 (10.6%)
18F-OC PET parameters, median (range)
SUVmax
56.79 (0-365.95)
SSTR-derived TV
38.16 (0-1278.86)
SRE
727.94 (0-52667.68)
18F-FDG PET parameters, median (range)
SUVmax
18.55 (0-151.08)
MTV
14.72 (0-956.23)
TLG
143.85 (0-21226.01)
Presence of metastases ( %)
Liver metastases
41 (62.1%)
Bone metastases
17 (25.8%)
Lymph node metastases
40 (60.6%)
Lung metastases
9 (13.6%)
CgA (positive, %)
55 (83.3%)
CEA (positive, %)
8 (12.1%)
NSE (positive, %)
8 (12.1%)
Tumor progression
Yes
45 (68.2%)
No
21 (31.8%)
aOthers included six patients with a mediastinum lesion origin, six patients with unknown primary sites, one patient with an origin in the throat, one patient with an origin in the breast, and one patient with an origin in the biliary tract. bMedical treatments included cold somatostatin analog and other anticancer drugs. cLiver-directed treatments included transcatheter arterial chemo- or radioembolization and microwave ablation for liver metastases. SSTR-derived TV: somatostatin receptor-derived tumor volume; SRE: somatostatin receptor expression; MTV: metabolic tumor volume; TLG: tumor lesion glycolysis; CgA: chromograninA; CEA: carcinoembryonic antigen; NSE: neuron-specific enolase; PFS: progression-free survival; IQR: interquartile range; PRRT: peptide receptor radionuclide therapy.
